VivoSim Labs 10-K Flags Going Concern, Nasdaq Breach, and a Deepening Cash Crisis
VIVS is trading near its 52-week low of $0.78 (11% above the low).
Summary
VivoSim Labs' 10-K discloses a going concern warning, a stockholders' deficit that breaches Nasdaq's minimum equity rule, and a cash balance too small to cover the next year's operations. The company's survival is in serious doubt.
Key Events · Earnings and Guidance · VIVS
-
Going Concern Warning
Citing recurring losses, negative cash flows, and insufficient capital, both management and the auditor express substantial doubt about VivoSim's ability to continue as a going concern.
-
Nasdaq Non-Compliance
A stockholders' deficit of $1.1 million as of March 31, 2026, violates Nasdaq's minimum equity rule; with the stock trading below $1, a bid price deficiency notice also looms.
-
Severe Cash Crunch
Cash on hand totaled only $5.0 million as of March 31, 2026, while expected FY2027 operating expenses reach $10.7 million. In FY2026, net cash used in operations was $10.8 million.
-
Dilutive Financing Overhang
The March 2026 offering included warrants with price protection and a cashless exercise feature that could force the issuance of up to 720 million shares if the stock price falls to $0.01, far exceeding the authorized share count.
Analysis · VIVS · Life Sciences
The annual report from VivoSim Labs reveals a rapidly deteriorating financial position. With just $5 million in cash against projected annual operating expenses of $10.7 million, both management and the auditor have voiced substantial doubt about the company's ability to continue as a going concern. A stockholders' deficit of $1.1 million has already triggered non-compliance with Nasdaq's minimum equity listing requirement, and the stock's sub-$1 price adds the risk of a delisting notice. Survival now depends on raising fresh capital, yet the deeply discounted March 2026 offering and the overhang of highly dilutive warrants may complicate any future financing. Adding to the pressure, a lawsuit with a key investment bank is pending, with oral argument scheduled for July 15, 2026. For investors, this is a critical warning.
At the time of this filing, VIVS was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.78 to $5.30. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.